Bristol-Myers Squibb (NYSE:BMY), a global biopharmaceutical giant with a market capitalization of $120.8 billion, finds ...
As the major cost-cutting initiative at Bristol Myers Squibb rolls on, the company has launched another round of layoffs in ...
Faced with the encroaching threats of patent expirations and generics, biopharma companies in 2024 invested 33% more in ...
Pfizer beats Q4 estimates with 24.9% revenue growth, reaffirming 2025 guidance and targeting $4.5 billion in cost savings ...
Cumberland Pharmaceuticals’ Duchenne muscular dystrophy (DMD) drug has improved the amount of blood pumped by the heart, ...
Request To Download Free Sample of This Strategic Report @ Highlighted with 36 tables and 83 figures, this 153-page report ?North America Biopharmaceuticals Market 2023-2033 by Product Type, Testing ...
Pfizer reported $63.6 billion in revenue for the full year, up 7% compared to 2023. The full-year revenue beat Wall Street ...
These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...
As we observe World Cancer Day today, let us look at some of the trends in cancer therapeutics expected to improve cancer ...
Cantor Fitzgerald updated its financial model for Bristol-Myers Squibb Co. (NYSE:BMY), leading to an increased price target on the company's stock. Analysts at the firm now see the price target at $55 ...
I’ve got my eye on four trends – the maturation of AI-powered drug development, fierce competition in the GLP-1 space, the ...
Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in ...